Abstract
Extensive researches within the last decade have supported the anti-inflammatory properties of curcumin. However, the development and clinical application of curcumin have been limited significantly by its instability and poor metabolic property resulting from the β-diketone moiety decomposition and phenolic glucuronides. In this paper, a curcumin derivative (A50) without β-diketone and phenolic hydroxyl groups was designed and reported. The X-ray diffraction analysis showed a more rigid structure of A50 than that of curcumin. A pharmacokinetic study of A50 in rats indicated that its metabolic parameters were significantly improved compared to those of curcumin. Furthermore, A50 exhibited stronger anti-inflammatory activity than curcumin did via the mechanism, at least partly, associated with inhibiting ERK and JNK phosphorylation in macrophages. These results suggest that the structural modification is both pharmacokinetically and pharmacologically beneficial, and A50 may be a promising anti-inflammatory candidate to treat various inflammatory diseases.
Keywords: Anti-inflammatory property, Curcumin, Crystal structure, (2E, 5E)-2, 5-bis(2, 5-dimethylbenzylidene) cyclopentanone, Mono-carbonyl analogue of curcumin, Pharmacokinetic profile.
Letters in Drug Design & Discovery
Title:Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50
Volume: 10 Issue: 6
Author(s): Xiangjian Chen, Luqing Ren, Xiuhua Zhang, Lu Guo, Jianmin Zhou, Guang Liang and Yi Wang
Affiliation:
Keywords: Anti-inflammatory property, Curcumin, Crystal structure, (2E, 5E)-2, 5-bis(2, 5-dimethylbenzylidene) cyclopentanone, Mono-carbonyl analogue of curcumin, Pharmacokinetic profile.
Abstract: Extensive researches within the last decade have supported the anti-inflammatory properties of curcumin. However, the development and clinical application of curcumin have been limited significantly by its instability and poor metabolic property resulting from the β-diketone moiety decomposition and phenolic glucuronides. In this paper, a curcumin derivative (A50) without β-diketone and phenolic hydroxyl groups was designed and reported. The X-ray diffraction analysis showed a more rigid structure of A50 than that of curcumin. A pharmacokinetic study of A50 in rats indicated that its metabolic parameters were significantly improved compared to those of curcumin. Furthermore, A50 exhibited stronger anti-inflammatory activity than curcumin did via the mechanism, at least partly, associated with inhibiting ERK and JNK phosphorylation in macrophages. These results suggest that the structural modification is both pharmacokinetically and pharmacologically beneficial, and A50 may be a promising anti-inflammatory candidate to treat various inflammatory diseases.
Export Options
About this article
Cite this article as:
Chen Xiangjian, Ren Luqing, Zhang Xiuhua, Guo Lu, Zhou Jianmin, Liang Guang and Wang Yi, Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50, Letters in Drug Design & Discovery 2013; 10 (6) . https://dx.doi.org/10.2174/1570180811310060010
DOI https://dx.doi.org/10.2174/1570180811310060010 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on the Development in the Field of NIDDM based Thiazolidinedione PPARγ Agonists
Mini-Reviews in Medicinal Chemistry Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets Domino/Cascade and Multicomponent Reactions for the Synthesis of Thiazole Derivatives
Current Organic Chemistry Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Azelaic Acid: A Promising Agent for Dermatological Applications
Current Drug Therapy Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Exposing “Bright” Metals: Promising Advances in Photoactivated Anticancer Transition Metal Complexes
Current Medicinal Chemistry Lyn Regulates Cytotoxicity in Respiratory Epithelial Cells Challenged by Cigarette Smoke Extracts
Current Molecular Medicine Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Flavonoid Kaempferol Inhibits the Proliferation and Survival of Human Leukemia HL60 Cells
Current Drug Therapy Drug Metabolism and Pharmacokinetics in Support of Drug Design
Current Pharmaceutical Design The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets Recent Trend for EGFR-Based and ALK-Based Targets: A Patent Analysis
Recent Patents on Anti-Cancer Drug Discovery N-Myristoyltransferase: A Novel Target
Mini-Reviews in Medicinal Chemistry